icon-folder.gif   Conference Reports for NATAP  
 
  64rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Washington, DC Nov 1-5 2013
Back grey_arrow_rt.gif
 
 
 
PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF FALDAPREVIR IN PATIENTS WITH DIFFERENT LEVELS OF RENAL IMPAIRMENT
 
 
  Reported by Jules Levin
The 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 1-5, 2013, Washington, DC.
 
F Huang1, V Moschetti2, B Lang3, A Halabi4, M Petersen-Sylla4, C-L Yong1, M Elgadi51Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 2Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; 3Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; 4CRS Clinical Research Services Kiel GmbH, Lornsenstrasse, Kiel, Germany; 5Boehringer Ingelheim Ltd, Burlington, Ontario, Canada

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif